Venture Financing in Biotech Follows Male CEOs and Boards

  • Only 5.4% of venture capital invested in biotechnology companies with women CEOs
  • Biotechnology companies with all-male boards garner 57% of all venture financing
  • Women just 3% of new CEO appointments in biotechnology

LONDON--Liftstream Ltd, a company providing executive recruitment services to the biotechnology sector, announces the publication of its new gender diversity report, "Investing in Biotechnology Management", a study of venture financing and hiring trends in European and US biotechnology companies and the gender representation on the boards and at the executive level. The research analyses 110 investment deals in private biotechnology companies as well as 308 biotech executive appointments.

The report details the board gender composition of private biotechnology companies who have achieved venture financing over a fixed period during 2014 and 2015, revealing specific data about the gender balance of those company boards and the executives leading them. Biotechnology companies across the European and US markets with all-male board of directors, raised 57% of the total capital invested. Of the total capital raised, only 5.4% of the capital allocated was invested in companies with a female CEO. Male CEOs were seen raising over $17 to every $1 raised by their female counterparts.

The 'Investing in Biotechnology Management' study also looks at executive hiring trends in the biotech sectors, charting 308 recent biotech appointments at the board, C-suite and function leadership level. The report reveals that just 17% of all appointments were women and only 3% of CEOs appointed to run biotechs were women.

Karl Simpson, CEO at Liftstream commented: "Having last year published the biotechnology sector's largest ever study of boardroom and executive gender diversity, we are pleased to reveal this new study. Our intention was to explore the strong relationship between venture financing in biotechs and the management and boards of those companies. With increasing evidence that gender diverse leadership delivers better returns, it was important to understand if the venture capital community were responding to this opportunity.'

'We have also looked at the biotech sector's executive hiring trends for indicators of increased levels of female representation across the C-suite and at the Board of Directors. Recruiting board and executive team members must be meritocratic but we have shown that the sector is heavily male dominated and the lack of structure and process around hiring is perpetuating this outlook.'

Liftstream continues to work with a global network of biotechnology and life science executives to develop further initiatives aimed at increasing both awareness and representation of women leaders in the biotech sector. To download the full free report visit: http://www.liftstream.com/investing-in-biotech.html

About Liftstream www.liftstream.com

Liftstream Ltd is a leader in executive recruitment services for the biotechnology sector; offering our clients a full capability to recruit board and executive leadership, as well as specialised expertise across the functions comprising R&D, Commercial and Operations. Founded in 2003, Liftstream has extensive sector knowledge which we use to advise and support our clients' hiring requirements and to deliver the highest quality people through a structured and rigorous search process. Liftstream provides services to its clients from London offices. We are supporters of equal opportunities and diversity.

 

Contacts

Enquiries:
Liftstream Ltd.
Karl Simpson, CEO
+44 (0) 20 3178 5864
[email protected]

 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.